Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

13 Pages (Click to Jump) V   1 2 3 4 > »    
 
  
Reply to this topic

MYX, MAYNE PHARMA LIMTED
nipper
post Posted: Dec 12 2018, 11:41 AM
  Quote Post


Posts: 5,398
Thanks: 1961


QUOTE
Why is the Mayne Pharma share price on the rise?

Investors have responded positively to news that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for its Tolsura 65mg capsules.

According to the release, Tolsura is a new formulation of itraconazole indicated for the treatment of certain systemic fungal infections in adult patients.

This includes the treatment of blastomycosis, histoplasmosis, and aspergillosis. These are serious infections that most commonly occur in vulnerable or immunocompromised patients such as those with a history of cancer, transplants, HIV/AIDS, or chronic rheumatic disorders, and are often associated with high mortality rates or long-term health issues.

Mayne Pharma’s CEO, Scott Richards, appeared to be pleased with the news and the potential for Tolsura.

He said: “We are very pleased to have received FDA approval of this patented formulation of itraconazole which incorporates Mayne Pharma’s proprietary SUBA technology to improve the bioavailability of poorly soluble drugs.”

Before adding that the company is “proud to offer a new treatment option for patients with these life-threatening infections. We believe physicians will appreciate having access to Tolsura, which has been shown in clinical studies to have increased bioavailability and significantly reduced variability when compared to conventional oral itraconazole capsules.”

What now?

The company plans to launch the product in January 2019 with a new institutional sales team focused primarily on hospital-based infectious disease specialists.

Management advised that the US anti-fungal triazole market is currently valued at US$600 million according to IQVIA. And based on the clear unmet clinical need in serious systemic infections, its addressable market is estimated at US$200 million.
Motley fool

- ... above 90c.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Sep 13 2017, 06:05 PM
  Quote Post


Posts: 5,398
Thanks: 1961


QUOTE
Mayne Pharma rallied 13 per cent to 73¢ .......... on the heels of generics industry leader Teva Pharmaceutical Industries, which surged 7 per cent in Tel Aviv on an asset sale proposal overnight.
shorters, show your heels?



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
blacksheep
post Posted: Aug 10 2017, 02:14 PM
  Quote Post


Posts: 5,699
Thanks: 2125


In Reply To: nipper's post @ Aug 10 2017, 01:09 PM

Heavy shorting yesterday - alert symbol, indicating the stock has been shorted more than o.5% on the day

Wed 9th Aug, 2017 12,023,706 1,532,124,251 0.78% 37,840,643 31.77%

https://www.shortman.com.au/stock?q=myx



--------------------
The herd instinct among forecasters makes sheep look like independent thinkers. Edgar Fiedler

If the freedom of speech is taken away then dumb and silent we may be led, like sheep to the slaughter. George Washington
 
nipper
post Posted: Aug 10 2017, 01:09 PM
  Quote Post


Posts: 5,398
Thanks: 1961


QUOTE
Drawing comment is the extension of a highly unusual "structured loan" facility MD Scott Richards has with Credit Suisse, which gives him "ongoing economic exposure" to around 7.3 million Mayne Pharma shares "within a range of prices".

The facility gives Richards the right to "deliver" these shares to Credit Suisse subject to a "collar arrangement", or, a floor on the value these shares can be considered at.

The concern is that by virtue of this collar, Richards could in effect have just over a quarter of the 25.5 million shares he's exposed to (either directly or through the executive loan scheme) insulated from the worst of Mayne Pharma's price recent falls. Since the disclosure of the increased facility was made on June 27, Mayne's share price is down 34 per cent, potentially making a collar very handy.

But there's another way of looking at this, say sources at the company. While the facility could act to limit the downside risk to some of Richard's shares, we're told that's far from its purpose. It was first entered into a year ago, with just 4.5 million shares, in order to give Richards the funds to take up his full entitlement of a capital raising this time last year to fund Mayne's Teva acquisition. In effect, the facility was intended to allow him to increase his exposure to Mayne Pharma, rather than to limit it. With the facility expiring this year, Richards had to either extend it, buy the shares outright or lose the exposure. He choose to extend the loan.

Richards, due to soon move to the US to keep a closer eye on the company's US operations, joined Mayne Pharma over five years ago, and in that time he's only increased his holdings (now worth far less than they were). The company's remuneration structure contains no short-term incentive but does provide executives with vesting options over stock. Richards had taken up all his entitlements – and had to fund that takeup.

Mayne Pharma is highly shorted, with 11.7 of its register leant out to short-sellers, who've been making a killing of late as its price has plunged 62.6 per cent in 12 months. Mayne's share price declined another 7.5 per cent on Wednesday, after reporting lower-than-expected earnings on Tuesday.
afr



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Aug 9 2017, 10:11 PM
  Quote Post


Posts: 5,398
Thanks: 1961


No uptick here
QUOTE
fierce competition in the United States' generic drug sector continues to weigh on earnings.

Mayne said on Tuesday revenue for the 2016-17 year would be $581 million, well below the analyst consensus for revenue of $624 million, according to Bloomberg.

Underlying earnings before interest, tax, deprecation and amortisation will be between $212 million and $216 million, compared with consensus forecasts of $226 million, while reported net profit will come in at between $92 million and $95 million. Analysts had been expecting profit of $118 million.

Shares in Mayne Pharma closed the day down 9.6 per cent to 80.5¢. The stock has now tumbled 60 per cent over the past 12 months, from a high of $2.11 on August 15, 2016, and remains one of the most shorted stocks
http://www.afr.com/business/health/pharmac...h#ixzz4pG9F8Fsu




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne

Said 'Thanks' for this post: early birds  
 
alonso
post Posted: Jul 6 2017, 10:28 AM
  Quote Post


Posts: 2,581
Thanks: 94


In Reply To: cooderman's post @ Jul 6 2017, 09:12 AM

Morningstar says undervalued and strong buy, but chart is bearish. It would be nice to see even a little uptick at the end.
I like to see some kind of div to collect as well as trade. Is that likely?



--------------------
"The optimist proclaims that we live in the best of all possible worlds. The pessimist fears this is true"

"What is prudence in the conduct of every private family can scarce be folly in that of a great kingdom." Adam Smith
 


cooderman
post Posted: Jul 6 2017, 09:12 AM
  Quote Post


Posts: 1,342
Thanks: 463


May be worth a risk if it finds sup. around the $1 again. Any fall below the recent low of .99 and best to stay out.

Attached Image



 
nipper
post Posted: May 4 2017, 10:59 AM
  Quote Post


Posts: 5,398
Thanks: 1961


QUOTE
Things have gone from bad to worse for the generic drug industry just as its biggest players are set to report earnings. The latest sign came late Tuesday. Embattled drugmaker Perrigo said that federal agents executed search warrants at company headquarters, as part of a wide-ranging investigation into price collusion in the generics industry. Shares fell more than 6% Wednesday morning.

Several other companies have received subpoenas as part of this investigation. The Government Accountability Office issued a report last year that found that prices of 300 out of 1,441 generic drugs doubled at least one time between 2010 and 2015.

True, a high standard of proof is required in collusion cases. Many federal inquiries end without charges or penalties. And generic drug stocks generally trade for very low earnings multiples. Those facts could give hope to investors when the largest generics companies report earnings next week.

While the investigation could weigh on long-term price increases for generics, there is a more immediate concern—generic drug prices are falling at an accelerating rate. Two small drugmakers joined the parade that has included big pharma companies and drug distributors who are seeing bigger declines in prices.

Lannett cited generic pricing pressure to explain subpar results on Tuesday. Shares fell by 16% on Wednesday. Australian generics company Mayne Pharma Group, which has a large U.S. business, said during its investor day earlier this week that increased pressure from buyers is driving down prices and predicted that declines in the second half of the year could reach as high as 15%.

The latest warnings come after bigger players gave pessimistic forecasts. Novartis said last month that its generic unit experienced price deflation of about 8% in the first quarter. Drug distributor Cardinal Health said last month it expects prices of generics to fall by a low double-digit percentage for the fiscal year ending in June.

Being able to raise prices is particularly important for many drugmakers right now. A slew of deal-making in the sector during the now-distant good times of 2014 and 2015 means companies levered up their balance sheets at the worst possible moment. Heavily indebted Perrigo, to name one example, is down more than 60% over the past two years.

There is no reason to believe that gloomy backdrop will show signs of improvement by next week.
Dow Jones Newswires

and then ..
QUOTE
Mayne Pharma Group has been forced by the ASX to defend this week's investor update after an earnings warning on its generic portfolio sunk its share price. The Australian Securities Commission sent the pharmaceutical company an "aware query" after Monday's release of Mayne's investor day presentation saw its shares slump from an opening price of $1.35 to a close of $1.20.

The company, in a 110-page investor day presentation*, said a tougher generic pricing environment in the second half of this year was expected to result in generic sales in its Teva portfolio falling below its original guidance.

The ASX warned in its letter to Mayne that it had previously experienced difficulties with announcements that had a innocuous header, such as "chairman's address to AGM", but had market sensitive material embedded in the release. "The ASX would ask entities that market sensitive announcements are made on a stand-alone basis and not embedded in other announcements that may not be market sensitive," the ASX told Mayne in its letter.
*on p.107



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: May 1 2017, 03:03 PM
  Quote Post


Posts: 5,398
Thanks: 1961


in a 110-page investor day presentation released today, Mayne Pharma MYX said a tougher generics pricing environment in the second half of 2017 was expected to result in generic sales in its Teva portfolio falling below its original guidance.

Chief executive Scott Richards also outlined at the investor day that the Teva portfolio gross profit margin was tracking ahead of 50 per cent of guidance and EBITDA was broadly in line.

"Upsides will include further FDA approvals and market share gains," he said. "There is a potential first-to-market opportunity on a $US250 million product, which has been granted expedited review."

- whoops ... down 10% ($1.21)



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 17 2016, 11:33 AM
  Quote Post


Posts: 5,398
Thanks: 1961


Mayne MYX down 9% to $1.30 ..... a price-fixing suit filed against six companies including Mayne in the US.

....... I am so glad I'm not in this one. Was, posted, sold early only to watch it rise. Not a "sleep at night" stock,...... (And incidentally, one company most 'mentioned in dispatches' by many a gun stock picker extolling his fund's superior performance, over the last few months - though the cat has got the collective tongue recently)



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
 


13 Pages (Click to Jump) V   1 2 3 4 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING